Based on this observation Sylentis is currently evaluating a topical treatment with small interfering oligonucleotide of RNA (SiRNA) targeted to block the human TRPV1, Tivanisran, in Phase 3 studies in dry eye patients (101). This evidence concerns the gene TRPV1 and dry eye syndrome.